Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

Vitamin D has immunomodulatory effects that might aid clearance of mycobacterial infection.

Dalhousie University and Infectious Diseases Training and Research Centre.

Who Took Part

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

Neither the patients nor the clinical and laboratory investigators and personnel were aware of treatment assignment.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Analysis was by modified intention to treat.

This trial is registered with ClinicalTrials.gov, number NCT00366470.

What Was Measured

PubMed files the paper under topics including Antibodies, Bacterial, Antitubercular Agents, Combined Modality Therapy, Dietary Supplements, Immunologic Factors, Mycobacterium tuberculosis and Sputum.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (The Lancet. Infectious diseases), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.